No Data
No Data
Yabao Pharmaceutical Group Co., Ltd. 2024 Semi-annual Report
Summary of the 2024 interim report of Yabao Pharmaceutical Group Co., Ltd.
Yabao Pharmaceutical Group (600351.SH) plans to spend between 0.1 billion yuan and 0.15 billion yuan to buy back shares.
Yabao Pharmaceutical Group (600351.SH) announced on August 14 that the repurchased shares will be cancelled in accordance with the law and the registered capital of the company will be reduced. The total amount of funds to be repurchased is not less than RMB 0.1 billion (inclusive) and not more than RMB 0.15 billion (inclusive), and the repurchase price does not exceed RMB 6.95 per share (inclusive).
Yabao Pharmaceutical Group (600351.SH): net income of 0.18 billion yuan in the first half of the year, a year-on-year increase of 6.99%.
Yabao Pharmaceutical Group (600351.SH) released its semi-annual report on August 14th. During the reporting period, the company achieved revenues of 1.444 billion yuan, a decrease of 5.82% year-on-year, and net income attributable to shareholders of the listed company of 0.18 billion yuan, an increase of 6.99% year-on-year. The company focuses on its advantages and resources to build a platform for the R&D of generic drugs, and focuses on the R&D of high-end generic drug products with high technological barriers and cost advantages. Currently, the company has established high-difficulty preparation technology platforms such as transdermal patches, complex injections, topical ointments, and sustained-release formulations, and has successfully promoted the R&D of pipeline products during the reporting period.
Yabao Pharmaceutical Group Gets Supplementary Drug Approval for High-Blood Pressure Tablets
Yabao Pharmaceutical Group (600351.SH): received a notification of approval for a pharmaceutical supplement application.
On August 12th, Glodon News reported that Yabao Pharmaceutical Group (600351.SH) announced that it has received an "Approval Notice of Drug Supplementary Application" (Notice No.: 2024B03619) issued by the National Medical Products Administration regarding Nitrendipine Sustained-release Tablets (I), which has passed the evaluation of consistency in quality and efficacy of generic drugs.
No Data